<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83506">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018198</url>
  </required_header>
  <id_info>
    <org_study_id>13-0830</org_study_id>
    <nct_id>NCT02018198</nct_id>
  </id_info>
  <brief_title>Clinical Performance Study of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Upper Respiratory Infection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Pathogen Screening</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rapid Pathogen Screening</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate FebriDx, a point-of-care, non-invasive, rapid
      diagnostic test, at identifying an immune response to viral and bacterial infection related
      to an acute community acquired febrile upper respiratory infection, as compared to expert
      clinical reviewers' evaluation in conjunction with the results of clinical standardized
      microbiologic and laboratory testing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The positive and negative agreement of the FebriDx test compared to expert clinical reviewers' evaluation in conjunction with the results of clinical standardized microbiologic and laboratory testing.</measure>
    <time_frame>2 hours</time_frame>
    <description>Positive agreement is the proportion of true positive cases of the FebriDx test compared to expert clinical reviewers' evaluation and the results of clinical standardized microbiologic, and laboratory testing. Negative agreement is the proportion of true negative cases of the FebriDx test compared to expert clinical reviewers' evaluation and the results of clinical standardized microbiologic and laboratory testing.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1225</enrollment>
  <condition>Acute Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Device testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fingerstick of blood will be applied to the FebriDx test</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FebriDx</intervention_name>
    <arm_group_label>Device testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        URI ARM INCLUSION CRITERIA

          -  2 years of age or older

          -  Exhibit or report temperature (oral or tympanic) of greater than or equal to 100.5째F
             within 3 days (72 hours) of enrollment

          -  Presents with at least one of the following symptoms: runny nose, nasal congestion,
             sore throat, cough, hoarse voice or shortness of breath beginning no earlier than 7
             days before enrollment

        URI ARM EXCLUSION CRITERIA

          -  Suspected of having lower respiratory infection (other than acute bronchitis)

          -  Receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in the last 30 days

          -  Immunocompromised state (e.g. HIV) or taking immunosuppressive or chemotherapeutic
             medications in the last 30 days

          -  Taking antibiotics or antiviral therapy in the last 30 days

          -  Received a live viral immunization in the last 30 days

          -  Significant trauma or burns (&gt; 5% total body surface area or full thickness (3rd째))
             in the last 30 days

          -  Major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the
             last 30 days

          -  Chronic fever greater than 7 days

          -  Suspected of having otitis media

        ASYMPTOMATIC ARM INCLUSION CRITERIA

          -  2 years of age or older

          -  Asymptomatic for a noninfectious illness who present to primary care and urgent care
             outpatient offices and emergency departments

        ASYMPTOMATIC ARM EXCLUSION CRITERIA

          -  Fever greater than or equal to 100.5째F (oral or tympanic) in last 14 days

          -  Cough

          -  Chills

          -  Dyspnea

          -  Nasal congestion

          -  Rhinorrhea

          -  Sore throat

          -  Hoarse voice

          -  Autoimmune or rheumatologic disease

          -  Suspected of having lower respiratory infection (other than acute bronchitis)

          -  Receiving interferon therapy (eg. MS, HIV, HBV, HCV) in last 30 days

          -  Immunocompromised state (eg. HIV) or taking immunosuppressive or chemotherapeutic
             medications in the last 30 days

          -  Taking antibiotics or antiviral therapy in the last 30 days

          -  Received a live viral immunization in the last 30 days

          -  Significant trauma or burns (&gt; 5% total body surface area or full thickness (3rd째))
             in the last 30 days

          -  Major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the
             last 30 days

          -  History of a myocardial infarction or stroke in the last 30 days

          -  Chronic bacterial infection or osteomyelitis

          -  Known chronic viral infections such as HIV, HCV, HBV, or CMV

          -  Active tuberculosis

          -  Acute or chronic (greater than 30 days) diarrhea and/or vomiting

          -  Urinary tract symptoms in the last 14 days

          -  Active skin, ocular, or neurologic infections

          -  Suspected of having otitis media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Kasper, RN</last_name>
    <phone>9415566361</phone>
    <email>kasper@rpsdetectors.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Sambursky, MD</last_name>
    <phone>9415561853</phone>
    <email>sambursky@rpsdetectors.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kurz, MD</last_name>
      <email>mckurz@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Kurz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of S. Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rodriguez</last_name>
      <email>mariarodriguez@crsouthflorida.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orbein Mallet</last_name>
      <email>orbein@communitymedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Medical Research - North Miami</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Filbin, MD</last_name>
      <email>mfilbin@partners.org</email>
    </contact>
    <investigator>
      <last_name>Michael Filbin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hou, MD</last_name>
      <email>phou@partners.org</email>
    </contact>
    <investigator>
      <last_name>Peter C Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Shapiro, MD</last_name>
      <email>nshapiro@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Nathan Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Eisele, RN</last_name>
      <phone>508-363-5286</phone>
      <email>jeisele@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Nathan Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amesha Parekh, MD</last_name>
      <email>parekh@doctoris.org</email>
    </contact>
    <investigator>
      <last_name>Amesha Parekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Schipani</last_name>
      <email>cralms@aol.com</email>
    </contact>
    <investigator>
      <last_name>Stephan C Sharp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley H Self, MD</last_name>
      <email>wesley.self@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wesley H Self, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyza Guerrero</last_name>
      <email>elyzaguerrero@benchmarkresearch.net</email>
    </contact>
    <investigator>
      <last_name>Darrell Herrington, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 26, 2016</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
